These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33494381)

  • 21. Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2.
    Seephetdee C; Buasri N; Bhukhai K; Srisanga K; Manopwisedjaroen S; Lertjintanakit S; Phueakphud N; Pakiranay C; Kangwanrangsan N; Srichatrapimuk S; Kirdlarp S; Sungkanuparph S; Chutipongtanate S; Thitithanyanont A; Hongeng S; Wongtrakoongate P
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34066016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice.
    Powell AE; Zhang K; Sanyal M; Tang S; Weidenbacher PA; Li S; Pham TD; Pak JE; Chiu W; Kim PS
    bioRxiv; 2020 Aug; ():. PubMed ID: 32869030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice.
    Powell AE; Zhang K; Sanyal M; Tang S; Weidenbacher PA; Li S; Pham TD; Pak JE; Chiu W; Kim PS
    ACS Cent Sci; 2021 Jan; 7(1):183-199. PubMed ID: 33527087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Nelson RE; Singh S; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    bioRxiv; 2020 May; ():. PubMed ID: 32511342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).
    Sunagar R; Prasad SD; Ella R; Vadrevu KM
    Front Immunol; 2022; 13():1063679. PubMed ID: 36569867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants.
    Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; García-Sastre A; Schotsaert M; Russell SJ
    bioRxiv; 2022 Dec; ():. PubMed ID: 36561187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
    García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
    J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
    Joyce MG; Chen WH; Sankhala RS; Hajduczki A; Thomas PV; Choe M; Martinez EJ; Chang WC; Peterson CE; Morrison EB; Smith C; Chen RE; Ahmed A; Wieczorek L; Anderson A; Case JB; Li Y; Oertel T; Rosado L; Ganesh A; Whalen C; Carmen JM; Mendez-Rivera L; Karch CP; Gohain N; Villar Z; McCurdy D; Beck Z; Kim J; Shrivastava S; Jobe O; Dussupt V; Molnar S; Tran U; Kannadka CB; Soman S; Kuklis C; Zemil M; Khanh H; Wu W; Cole MA; Duso DK; Kummer LW; Lang TJ; Muncil SE; Currier JR; Krebs SJ; Polonis VR; Rajan S; McTamney PM; Esser MT; Reiley WW; Rolland M; de Val N; Diamond MS; Gromowski GD; Matyas GR; Rao M; Michael NL; Modjarrad K
    Cell Rep; 2021 Dec; 37(12):110143. PubMed ID: 34919799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
    Joyce MG; Chen WH; Sankhala RS; Hajduczki A; Thomas PV; Choe M; Chang W; Peterson CE; Martinez E; Morrison EB; Smith C; Ahmed A; Wieczorek L; Anderson A; Chen RE; Case JB; Li Y; Oertel T; Rosado L; Ganesh A; Whalen C; Carmen JM; Mendez-Rivera L; Karch C; Gohain N; Villar Z; McCurdy D; Beck Z; Kim J; Shrivastava S; Jobe O; Dussupt V; Molnar S; Tran U; Kannadka CB; Zemil M; Khanh H; Wu W; Cole MA; Duso DK; Kummer LW; Lang TJ; Muncil SE; Currier JR; Krebs SJ; Polonis VR; Rajan S; McTamney PM; Esser MT; Reiley WW; Rolland M; de Val N; Diamond MS; Gromowski GD; Matyas GR; Rao M; Michael NL; Modjarrad K
    bioRxiv; 2021 May; ():. PubMed ID: 34013273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS-CoV-2 infection.
    Zhang Y; Lu M; Thongpan I; Xu J; Kc M; Dravid P; Trivedi S; Sharma H; Liang X; Kapoor A; Peeples ME; Li J
    J Med Virol; 2023 Apr; 95(4):e28687. PubMed ID: 36941778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
    van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
    mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells.
    Alpuche-Lazcano SP; Stuible M; Akache B; Tran A; Kelly J; Hrapovic S; Robotham A; Haqqani A; Star A; Renner TM; Blouin J; Maltais JS; Cass B; Cui K; Cho JY; Wang X; Zoubchenok D; Dudani R; Duque D; McCluskie MJ; Durocher Y
    Commun Med (Lond); 2023 Aug; 3(1):116. PubMed ID: 37612423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
    Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.
    Vandergaast R; Carey T; Reiter S; Lathrum C; Lech P; Gnanadurai C; Haselton M; Buehler J; Narjari R; Schnebeck L; Roesler A; Sevola K; Suksanpaisan L; Bexon A; Naik S; Brunton B; Weaver SC; Rafael G; Tran S; Baum A; Kyratsous CA; Peng KW; Russell SJ
    mSphere; 2021 Jun; 6(3):e0017021. PubMed ID: 34077262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
    González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
    Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice.
    Szurgot I; Hanke L; Sheward DJ; Vidakovics LP; Murrell B; McInerney GM; Liljeström P
    Sci Rep; 2021 Feb; 11(1):3125. PubMed ID: 33542325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs.
    Lara-Puente JH; Carreño JM; Sun W; Suárez-Martínez A; Ramírez-Martínez L; Quezada-Monroy F; Paz-De la Rosa G; Vigueras-Moreno R; Singh G; Rojas-Martínez O; Chagoya-Cortés HE; Sarfati-Mizrahi D; Soto-Priante E; López-Macías C; Krammer F; Castro-Peralta F; Palese P; García-Sastre A; Lozano-Dubernard B
    mBio; 2021 Oct; 12(5):e0190821. PubMed ID: 34544278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron.
    Teng IT; Nazzari AF; Choe M; Liu T; Oliveira de Souza M; Petrova Y; Tsybovsky Y; Wang S; Zhang B; Artamonov M; Madan B; Huang A; Lopez Acevedo SN; Pan X; Ruckwardt TJ; DeKosky BJ; Mascola JR; Misasi J; Sullivan NJ; Zhou T; Kwong PD
    bioRxiv; 2021 Dec; ():. PubMed ID: 35018379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development.
    Zak AJ; Hoang T; Yee CM; Rizvi SM; Prabhu P; Wen F
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.